Nash Trial Launch in Oct / Nov 2020 | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website

CORT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  3291 of 3318  at  9/9/2020 2:33:32 PM  by

BSR_Alan

The following message was updated on 9/9/2020 2:45:53 PM.

Nash Trial Launch in Oct / Nov 2020

  
Corcept's Phase 2a NASH Pilot Launches in Oct/Nov 2020
120 NASH Patients
Placebo vs. 600mg vs. 900mg New Formulation Miricorilant 
Randomized, Double-blind, Placebo-controlled Design
Liver Fat Content via MRI
Enhanced Liver Fibrosis (ELF) Score  
TLRs in Q2-2022 
 
It looks like full-on NASH not just NAFLD patients, and thus many (most?) will be obese. I am expecting successful changes in the liver fat content and ELF scores. Miricorilant should improve the metabolic metrics including weight. By itself, weight and fat reduction should strongly move the needle.
 
Reviewers want drugs that improve the liver independent of weight reduction. In animal models, miricorilant reduces appetite and improves metrics independent of weight. It also preferentially removes pathogenic white fat from the liver.

Nevertheless, if I was a clinician, I would desire both characteristics, but especially want my patients to lose weight. It is probably the best single thing that can be done for many NASH patients; the condition can quickly improve with immediate weight / fat reduction.  

NASH Clinical Trial Listing
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 104
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
3292 Re: Nash Trial Launch in Oct / Nov 2020 - seems a bit short and slow i760 0 9/9/2020 3:06:54 PM






Financial Market Data provided by
.


Loading...